Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy

Eribulin mesylate (hereafter referred to as “eribulin”), a synthetic analog of halichondrin B, is a microtubule-targeting chemotherapeutic agent (Mani and Swami, 2010; Swami et al., 2012). It can inhibit mitotic spindle formation by targeting the growth phase of microtubules, which results in increased apoptosis and decreased cell prolife ration (Jordan et al., 2005). This new mechanism of action is distinct from those traditional tubulin-targeting agents such as taxanes, paclitaxel and vinblastine (Dybdal-Hargreaves et al., 2015).

Source: Critical Reviews in Oncology Hematology - June 12, 2018 Category: Cancer & Oncology Authors: Bin Zhao, Hong Zhao, Jiaxin Zhao Source Type: research